Author:
Zarogoulidis P,Chatzaki E,Hohenforst-Schmidt W,Goldberg E P,Galaktidou G,Kontakiotis T,Karamanos N,Zarogoulidis K
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Reference74 articles.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
2. Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011; 29: 4436–4441.
3. Hosomi Y, Shibuya M, Niho S, Ichinose Y, Kiura K, Sakai H et al. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Res 2011; 31: 3449–3456.
4. Hunter TB, Manimala NJ, Luddy KA, Catlin T, Antonia SJ . Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res 2011; 31: 3193–3204.
5. Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH . Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007; 25: 418–423.
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献